REG - Sareum Holdings PLC - Patent Allowance in China

Sareum HoldingsAnnouncement

16/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240916:nRSP1990Ea&default-theme=true

RNS Number : 1990E  Sareum Holdings PLC  16 September 2024

Sareum Holdings plc

("Sareum" or the "Company")

Patent Allowance for Crystalline Forms of SDC-1801 in China

Cambridge, UK, 16 September 2024 - Sareum Holdings plc (AIM: SAR), a
clinical-stage biotechnology company developing next-generation kinase
inhibitors for autoimmune disease and cancer, is pleased to announce that it
has received a Notice of Allowance from the China National Intellectual
Property Administration. This notice pertains to a patent application
protecting certain crystalline forms of SDC-1801, a dual TYK2/JAK1 kinase
inhibitor being developed as a potential new therapeutic for a wide range of
autoimmune diseases.

The Chinese patent, application number 2021800259993, will provide significant
protection on several crystalline forms of SDC-1801 and in the methods of
their preparation. The Company anticipates the Chinese patent to be granted by
the end of 2024, subject to the fulfilment of certain formalities. This is the
first patent allowance protecting crystalline forms of SDC-1801 in any
territory. Patent applications in other key territories, including the US,
Europe, Japan are under review.

Dr John Reader, Sareum's Chief Scientific Officer, commented: "We welcome the
additional allowance from the Chinese Patent Office, building on the recent
approval of patents protecting the molecular structure of SDC-1801 in all
major territories. This patent, covering various crystal forms, complements
our existing molecular structure patents and extends the lifecycle of our
patent estate.  Combined with the encouraging data from the Phase 1a trial,
this strengthened IP position gives us greater confidence as we look to
advance SDC-1801 through clinical development, aiming to address unmet medical
needs in various autoimmune diseases."

- Ends -

For further information, please contact:

 Sareum Holdings plc

 John Reader, Chief Scientific Officer            01223 497700

                                                  ir@sareum.co.uk

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                      020 7409 3494

 Hybridan LLP (Corporate Broker)

 Claire Noyce                                     020 3764 2341

 ICR Consilium (Financial PR)

 Jessica Hodgson / Davide Salvi / Kumail Waljee   0203 709 5700

 

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing
next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases and has entered
Phase 1a/b clinical development with an initial focus on psoriasis.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com
(about:blank)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFSSAAIVLIS